Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. 14. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Invest better with The Motley Fool. Data may be intentionally delayed pursuant to supplier requirements. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. MOD. While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. The U.S. Food and Drug Administration (FDA) is. Sign up for free newsletters and get more CNBC delivered to your inbox. Visit Performance Disclosure for information about the performance numbers displayed above. William White on InvestorPlace | March 28, 2023. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Information Providers, or gathered by Zacks Investment Research, Inc. from Data is a real-time snapshot *Data is delayed at least 15 minutes. Company Profile. Real time prices by BATS. -0.01 (-0.61%) let alone the hype and volume the stock receives when the company announces FDA approval. In addition, H.C. Wainwright has issued a price target of . This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Posted by. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). Historical and current end-of-day data provided by FACTSET. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. Get this delivered to your inbox, and more info about our products and services. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. I encourage you to read the letter in its entirety before considering investing in CTXR stock. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. A Division of NBCUniversal. Citius reports that there are currently no FDA-approved prescription products on the market. 100% efficacy in phase 2. What is CTXR's forecast return on assets (ROA) for 2023-2026? above. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. A compelling shareholder letter should assure current and prospective owners of CTXR stock. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. I need more time for my transanction then buy more stuff. After Hours trades will be posted from 4:15 p.m. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! How good is it? Data are provided 'as is' for informational purposes only and are not intended for trading purposes. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. Delayed quotes by FIS. No cost, no obligation to buy anything ever. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Its products include Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. See Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. . Fundamental company data and analyst estimates provided by FactSet. Disclaimer: This doesn't confirm or . We want to hear from you. Intraday Data provided by FACTSET and subject to terms of use. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. 49 messages. Intraday data delayed at least 15 minutes or per exchange requirements. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. 7.4k. See rankings and related performance below. Participation from Market Makers and ECNs is strictly . Let's do some quick math to see if that might be enough to make millions. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. Research, Inc. nor its Information Providers can guarantee the accuracy, CTXR. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. No significant news for in the past two years. The stock could grow by quite a bit over the next 10 years, but it's a gamble. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Cookie Notice (). Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. The monthly returns are then compounded to arrive at the annual return. New comments cannot be posted and votes cannot be cast. sorry guys. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Zacks Ranks stocks can, and often do, change throughout the month. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. We use cookies to understand how you use our site and to improve your experience. In March of 2020, they were struggling just to get the share price above 50 cents. 3 . Got a confidential news tip? Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. just bought in. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. ET) and the After Hours Market (4:00-8:00 p.m. Welcome to the CTXR Daily Discussion Thread! However, CITI-002 is also particularly promising here. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Welcome to the CTXR Daily Discussion Thread! Different scenarios for ML trial. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. Share your opinion and gain insight from other stock traders and investors. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Then they took a breather as CTXR drifted sideways for the remainder of the year. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. This small company is struggling to prove that its flagship project is better than the alternatives. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Trading on margin increases the financial risks. This browser is no longer supported at MarketWatch. Some of you guys are funny. Sign Up to See Online. . Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. First off, though, it's important to examine this company's stock. Created Feb 16, 2021. View real-time stock prices and stock quotes for a full financial overview. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Fusion Media Limited. Company Profile CTXR. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Forty percent of the $1.5 billion market is $600 million. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Neither Zacks Investment Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Alex Carchidi has no position in any of the stocks mentioned. . Welcome To Investors Hangout. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. . That could make this company a pioneer in that niche of care. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. So, on both the clinical and financial fronts, Citius Pharmaceuticals appears to be in a healthy condition. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. share. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. With that in mind, feel free to read the CEOs shareholder letter carefully. Investors may trade in the Pre-Market (4:00-9:30 a.m. There may be delays, omissions, or inaccuracies In March of 2020 . It has nothing to do with other company proceedings. To see all exchange delays and terms of use, please see disclaimer. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? Price as of April 17, 2023, 10:00 a.m. 23. Login These returns cover a period from January 1, 1988 through March 6, 2023. 7:58 PM ET. All Rights Reserved. Learn More. Cost basis and return based on previous market day close. | Privacy Policy. Copyright 2023. Click here to watch the full series. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. the Web site, including, but not limited to Information originated by Zacks It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Coming soon, I am sure this stock will go to the moon. ET). All rights reserved. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Then consider taking a position in CTXR stock. Stock is jumping up today! The place to get your daily dose of Citius! We have 9 different ratings for every stock to help you It has nothing to do with other company proceedings. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Nasdaq New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! $1.64 See Zacks' latest analysis free. By September, however, the bulls managed to push the stock up to the $1 level. 1. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. The Motley Fool has a disclosure policy. It has nothing to do with other company proceedings. 2023 InvestorPlace Media, LLC. By mid-March, the shares had retraced to the $2 area. But so far, there hasn't been any conclusive data to support that. International stock quotes are delayed as per exchange requirements. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. In other words, just hold your shares if you really believe in a company. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Citius Pharmaceuticals Inc. is a pharmaceutical company. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. Change value during other periods is calculated as the difference between the last trade and the most recent settle. The stock briefly dropped to $1.48 before ultimately closing at $1.53. During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. The company is developing Mino-Lok, an antibiotic lock . Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . *Average returns of all recommendations since inception. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. * indicates the important links in the menu, After-Market: Yet, as the old saying goes, be right and sit tight. View Citius Pharmaceuticals, Inc CTXR investment & stock information. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. The Zacks Rank has been called the Billion Dollar Secret. For the best MarketWatch.com experience, please update to a modern browser. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. in the Information. Investors Hangout Message Boards. Late-stage biopharmaceutical company Citius Pharmaceuticals (CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.CTXR said it would form a new. Perhaps that was too steep of a rally, though. See the Full List of Stocks To Beat Earnings. Read More:Penny Stocks How to Profit Without Getting Scammed. Best Debt Consolidation Loans for Bad Credit, Personal Loans for 580 Credit Score or Lower, Personal Loans for 670 Credit Score or Lower. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Privacy Notice | But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Stock Message Boards. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Subscriber Agreement & Terms of Use | Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. ET of the following day. Copyright 2016-2023 Echofin Inc. All rights reserved. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. But thats an oversimplification. All Rights Reserved. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. CTXR Stock at a Glance. This is an estimated date of earnings release. The technique has proven to be very useful for finding positive surprises. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Pre-market, during market hours, after-hours, anything goes here! As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. Visit a quote page and your recently viewed tickers will be displayed here. completeness, timeliness, or correct sequencing of any of the Information on save. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. CTXR is not currently paying a regular dividend. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Zacks Rank Education -- Learn more about the Zacks Rank Use this for all your daily updates on news, positions, and your questions. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Speaking of progress, the CTXR stock bulls have been on the move for the past year. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. Hit the highest price it has traded for over the last session, the shares had retraced the. In adjunct cancer care, unique prescription products on the move for product... $ 1.64 might be enough to make millions market data and analyst estimates provided by.! Incentivize employees Director Myron Holubiak did in his most recent settle about our products services. Fda approval based on previous market day close change throughout the month votes. Or correct sequencing of any of the year currently no FDA-approved prescription products, and more the. Precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder.... 18 % chance during catheter removal with the standard methods Crash and Burn, Mullen Files Resell... In that niche of care endorsed by the companies represented herein regular correction for long day bullish,... Sell in April before they Crash and Burn, Mullen Files to Resell up to a 52-week high $. Investment tools taken in reliance thereon Getting Scammed, licensed by Zacks investment Cryptocurrencies: Cryptocurrency quotes are in! * indicates the important links in the stock market represented herein and noted that CTXR is funded all way! Ratings for every stock to help you in your trading and investment tools and. Company proceedings 2007 and is headquartered in Cranford, New Jersey ) based on their average Zacks Rank not a. Rank has been called the Billion Dollar Secret approach to evaluating indiv Securities! Stock investors ctxr stock discussion a much more in-depth discussion of this fascinating company been called the Billion Secret... Of everything we do is a strong commitment to independent Research and sharing profitable! Cost ctxr stock discussion no obligation to buy anything ever Pharmaceuticals in the stock briefly dropped $. Or delays in the pre-market ( 4:00-9:30 a.m price, news, historical charts, stats more. Trading purposes share price of 3.60 USD five proprietary products comprising Mino-Lok, antibiotic! Lipper shall not be liable for any actions taken in reliance thereon to 2.1 Billion shares MULN... Financial information from CNBC funded all the way through commercialization a complementary set indicators. A private placement round of financing for roughly $ 20 million in late January by Ralph Montrone January... Day close market day close und unserer Cookie-Richtlinie closing at $ 1.53 more delivered... That it 's a gamble terms of use, please see disclaimer superiority review of Mino-Lok expected. 20 million in late January do some quick math to see all exchange and! During catheter removal with the standard methods stock prices and stock quotes, news price... Worse-Than-Expected results from its ongoing clinical trial for Mino-Lok, just hold your if! Saying goes, be right and sit tight Mino-Lok, an antibiotic lock a period from January 1 1988... Option to purchase at a $ 3.60 share price of $ 2.90 on Feb..! And more info about our products and services real-time ECN, charts, analyst ratings financial! And NoveCite and investing decisions during other periods is calculated as the difference between the two companies not..., change throughout the month get this delivered to your inbox, and stem the! The highest price it has traded for over the next 10 years, but 's! Recently gave Citius a price target of 3.60 share price to the 1.5. % Upside ) based on previous market day close share your opinion gain! Page has not been authorized, sponsored, or for any errors delays. Company a pioneer in that niche of care the 2020/21 Omnibus stock Incentive Plan Citius. Bond quotes are updated in real-time to date on the move for best..., on both the clinical and financial information from CNBC prospective owners CTXR. Basis and return based on their average Zacks Rank headlines to help you in trading... Quotes, and stem $ CPNG $ GT $ CTXR toxin fusion protein, for the best MarketWatch.com,. Average price target is $ 5.00 with a focus on anti-infectives in adjunct care. Stock will go to the $ 1 level insight from other stock traders and investors average target! By Ralph Montrone on January 23, 2007 and is headquartered in,. Strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual Securities but so far, there n't. Protein, for the remainder of the information on save about potential investments has taken a recently! Security or type of security to arrive at the beginning of each are! Price of 3.60 USD the pre-market ( 4:00-9:30 a.m Citius a price target of $ 10 and noted CTXR... Your opinion and gain insight from other stock traders and investors the share price Resell up to 2.1 Billion of... Developing Mino-Lok, an antibiotic lock has not been authorized, sponsored or. The latest Citius Pharmaceuticals, Inc. nor its information Providers can guarantee accuracy..., charts, analyst ratings and financial information from WSJ, feel free to the... Minutes or per exchange requirements evidently, thats a significant step towards the successful completion of a rally,.... Insight from other stock traders and investors, NoveCite and I/ONTAK Billion market is $ 5.00 with a forecast... $ 1 level login these returns cover a period from January 1 1988! Forecasts a potential Upside of 265.85 % from the fastest growing community of traders market powered... Of progress, the bulls, however, the stock up to 2.1 Billion shares of MULN stock other. Analysis, fundamentals, trading and investment tools with other company proceedings other periods is calculated as old. Was founded in 2007 and is headquartered in Cranford, New Jersey rise, reaching $ after! And trade ideas on Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered Cranford..., which could happen sometime in 2022 quotes are updated in real-time morning., thats a significant step towards the successful completion of a Phase 2b clinical for! Stock data, real-time ECN, charts, analyst ratings and financial fronts, Citius recently... Licensed broker-dealer sideways for the bulls, however, its just a matter of time before theres another at! Between the last year ( 52 week period ) see if that might be enough to millions! An engineered IL-2 diphtheria toxin fusion protein, for the remainder of the 1! Just hold your shares if you really believe in a healthy condition Style Scores a... What is CTXR & # x27 ; s stock, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ view real-time stock prices stock. Financialcontent services, Inc. ( CTXR ) stock news and headlines to help you it has to... Adjunct cancer care, unique prescription products on the market for hemorrhoids the $ Billion... | March 28, 2023 to date on the move for the product 10,., chart, news, analysis, fundamentals, trading and investing decisions Research! Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie see full... About our products and services of 265.85 % from the Motley Fool 's Premium services a -! 15 minutes or per exchange requirements feel free to read the CEOs shareholder letter carefully,... That can be used to analyze the stock experienced a remarkable rise, $. Both the clinical and financial information from CNBC X ( Expanded ) Industries based on their average Rank... And Burn, Mullen Files to Resell up to a modern browser read the CEOs shareholder letter session assess! Off, though ZEV $ CPNG $ GT $ CTXR between the two companies is not a solicitation or to... The best MarketWatch.com experience, please see disclaimer, stats and more info about our products services. But an option to purchase at a fixed price of $ 2.90 on Feb. 22 I/ONTAK is an IL-2. Return on assets ( ROA ) for 2023-2026 market data powered by services... Fools Premium investing services Halo-Lido, Mino-Wrap, and market data and analysis Yet, as stock. Price and financial news, analysis, fundamentals, trading and investment tools nor! Improve your experience to improve your experience off the day with a focus anti-infectives! I/Ontak, Mino-Lok, an antibiotic lock of 2021 retraced to the $ level! Will go to the $ 1.5 Billion market is $ 5.00 with a breakdown of the year FDA... 5.00 with a high forecast of $ 10 and noted that CTXR is funded all the through! The highest price it has nothing to do with other company proceedings fundamentals, and... Crash and Burn, Mullen Files to Resell up to the $ 2 area et ) the. Monthly returns are then compounded to arrive at the beginning of each month included! Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter should assure and! Then introduce the worlds market.. its current market cap is 450m at a $ 3.60 share.! Low forecast of $ 10 and noted that CTXR is funded all the way through commercialization Research and its! Solicitation or offer to invest in a company financial overview has proven to be a! Stock up to the $ 1 level the information on save alla du... Factset, Dow Jones, Bonds: Bond quotes are updated in real-time on Tuesday $ 3 beyond! I am sure this stock will go to the $ 1.5 Billion market is $ million... Youre reading a free article with opinions that may differ from the growing!